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Running title: CHO Protein Predicted Immunogenicity (CHOPPI) 
Abstract 
Despite high quality standards and continual process improvements in manufacturing, host cell protein (HCP) 
process impurities remain a substantial risk for biological products. Even at low levels, residual HCPs can induce a 
detrimental immune response compromising the safety and efficacy of a biologic. Consequently, advanced-stage 
clinical trials have been cancelled due to the identification of antibodies against HCPs. To enable earlier and rapid 
assessment of the risks in Chinese Hamster Ovary (CHO)-based protein production of residual CHO protein 
impurities (CHOPs), we have developed a web tool called CHOPPI, for CHO Protein Predicted Immunogenicity. 
CHOPPI integrates information regarding the possible presence of CHOPs (expression and secretion) with 
characterizations of their immunogenicity (T cell epitope count and density, and relative conservation with human 
counterparts). CHOPPI can generate a report for a specified CHO protein (e.g., identified from proteomics or 
immunoassays) or characterize an entire specified subset of the CHO genome (e.g., filtered based on confidence in 
transcription and similarity to human proteins). The ability to analyze potential CHOPs at a genomic scale provides a 
baseline to evaluate relative risk. We show here that CHOPPI can identify clear differences in immunogenicity risk 
among previously validated CHOPs, as well as identify additional ‘risky’ CHO proteins that may be expressed during 
production and induce a detrimental immune response upon delivery. We conclude that CHOPPI is a powerful tool 
that provides a valuable computational complement to existing experimental approaches for CHOP risk assessment 
and can focus experimental efforts in the most important directions. 
Keywords: biologic, CHO, host cell protein, immunogenicity, T cell epitope, immunoinformatics 
Introduction 
Recombinant protein therapeutics have revolutionized the treatment of a wide variety of illnesses, with over 200 
different biopharmaceuticals licensed and generating nearly 100 billion dollars in global sales (Walsh, 2010). 
Genetically engineered host cells are generally used to manufacture these biologics (Jayapal et al., 2007). Chinese 
Hamster Ovary (CHO) cells are one of the most common such systems; e.g., 70% of recently approved therapeutic 
glycoproteins are produced in CHO cells (Higgins, 2010). A key advantage of CHO cells is their human-compatible 
post-translational modifications, particularly glycosylation, leading to improved therapeutic efficacy and protein 
longevity as well as increased safety (Omasa et al., 2010). Moreover, methods for cell transfection, gene 
amplification, and clone selection are well characterized in CHO cells, as are techniques to volumetrically scale 
production of complex therapeutics (Kim et al., 2012). 
Like all other such processes, CHO-based protein production faces the potential problem of impurities in the final 
product that can lead to undesired effects upon administration. One particular concern is host cell proteins (HCPs). 
These are also known as “hitchhiker” proteins, which are synthesized in the cell and not fully removed during 
purification. In general, quite a few residual HCPs may remain in the final product despite close monitoring and high 
standards throughout downstream processing (Champion et al., 2005). Unfortunately, even at low levels HCPs may 
induce a detrimental immune response, contributing to the overall immunogenicity of the product (Champion et al., 
2005); consequently, detection of anti-HCP antibodies following exposure to the therapeutic product has resulted in 
the cancellation of advanced clinical trials (Ipsen, 2012). In order to assess and mitigate the immunogenicity risk 
posed by HCPs in a particular protein production process, two questions must be addressed: what HCPs may be 
present, and how likely they are to stimulate a detrimental immune response. 
Substantial work is done during downstream processing in order to identify and eliminate most impurities. Detection 
is typically performed with standard immunoassay and proteomic methods, such as enzyme-linked immunosorbent 
assays (ELISAs) and Western blotting. More recent techniques, such as differential gel electrophoresis and liquid 
chromatography combined with mass spectrometry, have also been used to identify CHO proteins in greater detail 
(Doneanu et al., 2012; Jin et al., 2010). However, HCPs are a complex and a heterogeneous group of impurities, with 
substantial differences in isoelectric point, structure, molecular mass, and hydrophobicity properties. Host expression 
system, subcellular localization of expression, culture condition, purification process, and the target protein being 
produced all affect HCP composition and abundance, and some protein products may interact in a covalent fashion 
with specific HCPs (Pezzini et al., 2011). Thus, HCPs may differ from one product to another even when 
manufactured using the same cell line; therefore, attention must always be given to monitoring residual HCPs.  
While identification of residual protein impurities is important, additional analysis is required to characterize the 
resulting potential for a detrimental immune response upon delivery to patients. One powerful technique for 
immunogenicity analysis relies on immunoinformatics tools, which have been shown to make reliable predictions 
useful for and validated within the design of both biotherapeutics (Koren et al., 2007; Moise et al., 2012; Osipovitch et 
al., 2012) and vaccines (Gregory et al., 2009; Moise et al., 2011; Moss et al., 2011). Of particular relevance to HCP-
driven immunogenicity is the T cell pathway, in which an antigen-presenting cell processes a foreign protein into 
constituent peptides, some of which (the “epitopes”) are recognized by major histocompatibility complex (MHC) class 
II proteins and brought to the cell surface for inspection by T cells. The formation of a ternary MHC : epitope : T cell 
receptor complex drives the initial naïve response and can stimulate subsequent B cell activation and maturation. 
Thus, much immunoinformatics research has been directed toward highly-reliable prediction of putative T cell 
epitopes (Wang et al., 2008; De Groot and Martin, 2009), and the EpiMatrix system is one heavily-validated method 
based on peptide : MHC binding profiles (De Groot et al., 1997; De Groot et al., 2004). In addition to identifying 
individual epitopes within a protein, EpiMatrix can then also assess the overall immunogenicity risk of a protein 
according to its epitope density relative to benchmark proteins (Koren et al., 2007; De Groot and Martin, 2009). 
Publication of the CHO genome in 2011 (Xu et al., 2011) made it possible to examine the entire genome for 
potentially immunogenic proteins, using well-validated epitope prediction tools (Gutierrez et al., 2012).  
The immunogenicity of a CHO protein may be mitigated by the fact that it is quite similar to a human protein. 
However, some believe that “any protein is potentially immunogenic” (Worobec and Rosenberg, 2004) and proteins 
full of T cell epitopes are even more so, particularly when delivered in an unnatural fashion. Cases of severe adverse 
immune responses to autologous proteins have been published (Casadevall et al., 2002; Koren et al., 2002). 
Moreover, there are a number of animal models in which imperfect homology between an antigen and a host-origin 
protein contributes to the development of antibody responses to the protein (Inaba et al., 2009; Prasad et al., 2012). 
The response against the non-homologous epitope can then “spread” to other epitopes, even if they are host-like 
(Grosenbaugh et al., 2011). 
The JanusMatrix method (Moise et al., 2013) provides a means to balance these concerns, refining epitope-based 
immunogenicity analysis with a characterization of the “human-ness” of the predicted epitopes. In particular, 
JanusMatrix evaluates the potential for cross-reactivity of predicted epitopes with counterpart peptides in the human 
genome. Putative epitopes with little homology to the human genome are more likely to drive a T effector response, 
while epitopes that are conserved are more likely to be tolerated by the human immune system (He et al., 2014). The 
epitope-level cross-reactivity analysis of JanusMatrix thereby complements the characterization of protein-level 
homology, enabling identification of more worrisome epitopes that are unique to the HCP.  
This paper presents a new tool called CHOPPI (for CHO Protein Predicted Immunogenicity), available at 
http://www.immunome.org/CHOPPI, that unifies the two aspects of immunogenicity risk posed by CHO proteins 
(CHOPs) that may remain as process-related impurities: the potential presence of CHOPs (expression and 
secretion), and their potential immunogenicity (T cell epitope content predicted by EpiMatrix and human-ness 
assessed by JanusMatrix). Figure 1 illustrates the CHOPPI tool. In the “CHOP query” scenario a CHOP has already 
been identified experimentally (e.g., by immunoassays or proteomics), and CHOPPI is queried using its amino acid 
sequence, name, or accession number (entered in the text box in panel a), leading to a list of matches for further 
analysis (panel b). In a second scenario, called “genome filter,” CHOPPI searches a CHO genome for CHOPs 
meeting user-adjustable criteria regarding expression, secretion, and human homology (options in panel a), again 
leading to a list of possible CHOPs for inspection (panel c). Finally, validated CHOPs from the literature can be 
directly browsed (panel d). In all cases, drilling down on a particular protein yields a report (panel e) in which the 
protein is characterized in terms of both potential presence in the product and potential immunogenicity in humans, 
with a genomic-scale analysis providing a baseline for comparison. 
In a first test of the CHOPPI tool, we characterized a set of validated CHOPs identified in experimental recombinant 
protein preparations and found that while some appeared to pose little immunogenicity risk, others had patterns of 
epitope content indicative of the increased potential for an adverse response in patients. Using the CHOPPI tool, we 
also identified a number of other CHOPs that, if they happened to hitchhike into a particular preparation or during a 
particular process, could pose a substantial immunogenic risk due to large and/or relatively CHO-unique (i.e., 
dissimilar to human) epitope content. Finally, we characterized trends over the entire CHO-K1 genome, both to 
calibrate the evaluation of individual proteins of interest as well as to assess the expected risk over all possible 
CHOPs. We found that there is reason to be concerned about the potential immunogenicity of some CHO proteins – 
there are a number of CHO proteins predicted to be highly immunogenic and that could appear during production. At 
the same time, CHOPPI can provide guidance regarding CHO proteins that are of lower risk according to these 
criteria. These results illustrate that by integrating genomic-scale predictions of CHO protein immunogenicity risk, 
CHOPPI provides an important new resource for assessing impurity risks. While the assessment is purely 
computational and predictive in nature, it can guide further experimental efforts (e.g., detection and immunogenicity 
assays) and ultimately the development of effective and safe biotherapeutics for human use. 
Materials and Methods 
Evaluating the immunogenicity risk of CHOPs involves two considerations: which proteins are likely to be present 
from a process, and how likely they are to be immunogenic. CHOPPI allows a user to select proteins of interest for 
possible presence either by simply specifying them or by filtering a CHO genome according to criteria relevant to 
process-related impurities. CHOPPI then assesses the immunogenicity of selected proteins by reporting predicted T 
cell epitope content according to EpiMatrix, as well as by comparing them to their human homologs and comparing 
their predicted epitopes to predicted epitopes within the human genome (Figure 1). 
CHOP selection 
The “CHOP query” usage of CHOPPI allows a user to specify a protein of interest, perhaps one identified through 
experimental techniques (Figure 1(a,b)). The protein can be specified by accession number, name, or an amino acid 
sequence fragment. When an amino acid sequence is used as a query, CHOPPI uses BLAST (version 2.2.27+ 
(Camacho et al., 2009)), to search for homologs in a specified CHO genome; E-value and percent identity are 
reported. This application of CHOPPI enables users to determine the potential immunogenicity of a single CHOP or 
set of CHOPs, using the CHOPPI toolkit. See below for additional information on the CHOP query tool.  
The “genome filter” usage (Figure 1(a,c)) starts with a specified CHO genome and filters it according to user-
specified criteria evaluating potential for expression and secretion, along with similarity to human proteins. The 
possible filters (Figure 2) include matching to a CHO transcriptome, CHO proteome, mouse secretome, and human 
genome, and testing for a predicted signal peptide. Homology matching is based on results from BLAST according to 
user-specified sequence identity and coverage thresholds. Note that, except for the transcriptome, all sequences are 
amino acid sequences, previously translated and annotated from the relevant genomic data. This application of 
CHOPPI enables the identification of potentially immunogenic proteins that might be suitable for targeted 
downregulation in CHO protein production, if reduced immunogenicity is a desired outcome. See below for further 
illustration of the genome filter tool.  
The data sources for CHOP query and genome filter are as follows: 
CHO genome. All CHO proteins used in CHOPPI are derived from translated, annotated genomic sequence 
information. CHOPPI currently includes information from two genome projects, one for the commonly used CHO-K1 
cell line (Xu et al., 2011) and the other for the 17A/GY strain (Brinkrolf et al., 2013). Others (e.g., Lewis et al., 2013) 
will be incorporated as protein-level information becomes available. We note that the CHOPPI analysis is all in terms 
of the basal cell lines. The CHOPPI sequence database can be extended in future iterations to include modifications 
that are present in any derivative cell line that is being employed in a particular process. 
CHO transcriptome. Gene expression is, in part, tissue-specific, and thus genes expressed in the ovary cells, and 
not just present in the genome, are most likely to be present in CHO cell cultures. CHOPPI thus allows CHOPs from 
the genome to be filtered down to those with homology matches in the CHO-K1 transcriptome (Becker et al., 2011). 
CHOPs are homology-matched to translated transcripts via the “tblastn” form of BLAST, recognizing that proteins 
spanning contigs will be unfortunately dropped from the results. 
Proteome. To further focus on proteins that have been translated, we have compared the genes against the 
sequences (both proteins and glycoproteins) identified by the proteomic analysis (Baycin-Hizal et al., 2012). This 
extensive proteomic study employed a combination of gel electrophoresis, multidimensional liquid chromatography, 
and solid phase extraction of glycoproteins, followed by tandem mass spectrometry, in order to identify a total of 
6164 proteins at a false discovery rate of 0.02. The deposited identified proteins were homology-matched to the 
genomes in CHOPPI via “blastp”. 
Mouse secretome. Any expressed protein may be extracted as a hitchhiker, but secreted proteins may be 
considered even more likely to be present in CHO cell supernatant irrespective of target therapeutic protein. In lieu of 
a CHO secretome, CHOPPI characterizes potential secretion of CHOPs by homology matching to a set of secreted 
mouse proteins obtained from two databases, LOCATE and UniProt (Sprenger et al., 2008; UniProt Consortium, 
2012). 
Predicted signal peptides. As an alternative or complement to filtering against the relatively small and homology-
derived set of secreted proteins, secretion status may be predicted by the presence of a signal peptide in the CHOP. 
In order to identify which proteins from the CHO genome contain predicted signal peptides, CHOPPI employs 
SignalP version 4.1, which has been shown to be a very accurate predictor; e.g., it obtained a Matthews Correlation 
Coefficient of 0.874 in cross-validated signal peptide identification within a eukaryote dataset (Petersen et al., 2011). 
Validated CHOPs. While only a relatively small number of CHOPs have been previously identified experimentally, 
CHOPPI provides the ability to restrict analysis to those proteins. The set of CHOPs that is integrated into the 
CHOPPI tool will be updated when additional CHOPs are identified; a web form is provided for users to alert CHOPPI 
administrators to additional data. For the current application, the CHO genome was homology-matched to a set of 
CHOPs previously identified in biotherapeutic protein products (Doneanu et al., 2012; Pezzini et al., 2011). We 
filtered the listed proteins to those whose names were unambiguous, and matched them against the genome using 
stringent homology thresholds of 90% identity at 90% coverage to ensure the best matches. The matches were 
further processed in order to obtain a high-quality set of 26 CHOPs: sequence matches with mismatched names 
were eliminated (e.g., “actin cytoplasmic 1” was taken while “actin cytoplasmic 2” was dropped) and longer matches 
were chosen over corresponding shorter ones (e.g., for “elongation factor 2”). Furthermore, perlecan was also 
eliminated because it is only a small fragment of the alternative match “basement membrane-specific heparan sulfate 
proteoglycan core protein”. A full list of the resulting 26 CHOPs, including their GenBank accession numbers, is 
provided in the supplementary material and on the CHOPPI website.  
Human genome. A search for relevant CHOPs may be focused on those more or less similar to human proteins. If a 
particular human protein is relevant, then a CHOP query will find it via BLAST. If the general extent of human 
homology is important, then a genome filter can specify both an upper bound (i.e., only proteins with at most that 
much homology) and/or a lower bound (i.e., at least that much homology). An upper bound is useful to find CHOPs 
that are relatively divergent from human counterparts and thus pose general immunogenicity risk, while a lower 
bound is useful to find those that are relatively human-like, but may be distinct at the level of individual T cell 
epitopes, another form of risk as further discussed below. The human proteins considered are from the UniProt 
Reviewed database (UniProt Consortium, 2012). 
Immunogenicity analysis 
Immunogenicity analysis of selected CHOPs is based on EpiMatrix, a “pocket profile” method that assesses 
interactions of peptides with the binding pockets of the most prevalent MHC types in the human population (McMurry 
et al., 2005; Moise et al., 2011; Moss et al., 2011). CHOPPI uses EpiMatrix to predict binding against a common, 
representative set of eight class II HLA alleles (DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, and 1501) that 
“cover” the genetic backgrounds of most humans worldwide (Southwood et al., 1998). It thresholds EpiMatrix scores 
to select as epitopes only those peptides scoring in the top 5%; this threshold has been shown to identify peptides 
that are highly likely to bind the HLA molecule as predicted (De Groot et al., 1997). CHOPPI also employs the 
EpiMatrix whole-protein immunogenicity score to characterize the epitope density of a target protein relative to a 
background distribution (Diamond, 2003). In general, proteins having higher epitope densities (EpiMatrix whole-
protein score >20) tend to be more immunogenic, while low-density proteins (< −20) tend to be immunologically inert 
(De Groot and Martin, 2009; Hai et al., 2009).  EpiMatrix has been extensively applied and validated in the 
development of vaccines and therapeutic proteins as discussed in the Introduction, and benchmark tests have shown 
it to have an average sensitivity of 77% for HLA class II predictions, 5-17% better than that of a variety of other 
methods (De Groot and Martin, 2009). 
T cells that respond to autologous epitopes may be deleted in the course of immune system maturation (thymic-
dependent tolerance), and peripheral regulatory T cells that recognize autologous epitopes may actively suppress the 
immune response (peripheral tolerance). Thus, selected epitopes in CHOPs that are similar to autologous peptides 
may be actively tolerizing or at least non-immunogenic. Consequently, the raw epitope count and EpiMatrix whole 
protein score may overestimate immunogenicity by counting CHOP epitopes that are actually “human-like.” To help 
correct for this, CHOPPI also identifies the number of CHO-unique epitopes in a protein (i.e., those that are more 
likely to induce a detrimental immune response). Recognizing that due to T cell receptor (TCR) cross-reactivity of a 
CHOP epitope, the homology with human epitopes need not be exact in order to reduce immunogenicity risk, we 
employ the JanusMatrix tool that evaluates TCR cross-reactivity (Moise et al., 2013). A JanusMatrix-identified cross-
reactive CHO/human epitope pair must have identical TCR-facing residues (positions 2, 3, 5, 7, and 8 for class II) but 
can have variations of the MHC-facing residues (positions 1, 4, 6, and 9) as long as they are still predicted by 
EpiMatrix to bind the same MHC allele. Cross-reactive pairs are thus likely to be presented by the same MHC to the 
same TCR. We have shown that a JanusMatrix-based immunogenicity score is different for T effector epitopes 
versus those that are T regulatory or null, with statistical significance (He et al., 2014). The CHO-unique epitope 
count thus assesses how many peptides are likely to contribute to a detrimental immune response, as they are not 
cross-reactive with the human genome.  
Web tool 
The CHOPPI web tool is available from http://www.immunome.org/CHOPPI. It is free for academic users, subject to a 
registration step to ensure appropriate use.  For adaptations to other host cell lines and for use by commercial 
entities, readers are referred to the contact information on the above website.   
To support rapid CHOPPI analysis, an SQLITE (http://www.sqlite.org) database was constructed to store and index 
the annotated CHO genomes, homology matches across the input databases, and immunogenicity analyses. The 
NCBI BLAST executable, version 2.2.27+ (Camacho et al., 2009), was used to match the protein products from the 
CHO genomes, the contigs from the CHO transcriptome, the proteins from the CHO proteome, mouse secretome, 
the human genome, and the validated CHOP sequences. Homology matches at discrete sets of different percent 
identity and percent coverage thresholds were stored in the database. EpiMatrix immunogenicity scores, epitope 
counts, and JanusMatrix-based CHO-unique epitope counts were computed for each protein in the CHO genome, 
and stored in the database. 
The CHOPPI web tool is implemented in PHP. A CHOP query request looks up a protein in the database by name or 
accession, or invokes BLAST to find it by amino acid sequence. A genome filter request processes a form specifying 
homology filters, performs the appropriate query to retrieve matches from the preprocessed database, and renders 
the resulting dataset in either HTML tables (sortable by column) or CSV format. Individual protein reports summarize 
the immunogenicity analyses and detail the homology matches with links to relevant NCBI, UniProt, and LOCATE 
entries. Immunogenicity scores are also plotted, using the “Raphael” Javascript package (http://raphaeljs.com), 
relative to a background distribution over the CHO genome. 
Data analysis and visualization 
Additional figures were developed for the Results section, in order to present some of the findings obtained from the 
CHOPPI site. 
To characterize genomic-scale immunogenicity patterns, the EpiMatrix immunogenicity score and epitope 
distributions over sets of proteins (the whole genome, transcriptome, proteome, etc.) were analyzed and plotted in R 
(http://www.r-project.org). For large sets, smoothed histograms were generated and visualized via kernel density 
estimates computed by the “density” function. Cumulative distributions were generated by the “ecdf” function. 
Coarse-grain histograms were produced by the “hist” function. 
To illustrate the patterns of cross-reactivity between particular CHO proteins and human proteins, Cytoscape 
(Shannon et al., 2003) was used to generate graphical representations of networks of cross-reactive epitopes (Moise 
et al., 2013). In these networks, CHO and human proteins, along with their constituent epitopes (restricted to cross-
reactive ones on the human side) are represented with different symbols. Edges connect cross-reactive CHOP and 
human epitopes, as well as proteins with their constituent epitopes. 
Results and Discussion 
We applied CHOPPI to a variety of CHOP queries and genome filters in order to demonstrate its effectiveness at 
characterizing the immunogenic risk posed by CHOPs. We first used CHOPPI to assess the set of 26 validated 
CHOPs. We then used it to filter the CHO genome by different criteria in order to characterize immunogenicity 
patterns in genomic subsets. Finally, we selected and further detailed some CHOPs in different immunogenicity risk 
classes.  
Illustration of the CHOP Query Tool: Validated CHOPs 
Figure 3(a,c,e) illustrates the immunogenicity analysis of the 26 validated CHOPs derived from the literature; a 
detailed spreadsheet is in the supplementary material and an interactive version is available on the CHOPPI website. 
We see that the validated CHOPs have a range of EpiMatrix immunogenicity scores and epitope content. Notably, 
four of these proteins have EpiMatrix immunogenicity scores exceeding 20, which is considered to be higher risk for 
immunogenicity (‘risky’), yielding the secondary peak in the distribution in Figure 3(a): annexin A1 (24.9), glutathione 
S-transferase P (25.2), lysosomal protective protein (34.4), and collagen alpha-1(III) chain (35.8). The collagen chain 
is quite large, with 1051 amino acids and a total of 228 predicted epitopes (Figure 3(c)). Of those 228 epitopes, 60 
are unique to CHO, yielding the secondary peak in Figure 3(e). For reasons discussed above, we consider epitopes 
that are unique to CHO to be higher risk than epitopes that are conserved with the human genome.  
Lysosomal protective protein is also fairly large, containing 109 predicted epitopes over its 475 total amino acids, with 
28 of those epitopes being unique to CHO. The other two are smaller but still have substantial epitope content: 45 
epitopes (14 unique) in the 221 amino acids of glutathione S-transferase P and 75 epitopes (20 unique) in the 346 
amino acids of annexin A1. 
Figure 4 (left) illustrates the cross-reactivity patterns of two of these relatively risky proteins (lysosomal protective 
protein and annexin A1), along with a contrasting protein (metalloproteinase inhibitor 2) that has low overall 
immunogenicity and only one CHO-unique epitope (of 29 epitopes). As noted above, the two riskier proteins 
(lysosomal protective protein and annexin A1) both have sizable fractions of CHO-unique epitopes, clustered toward 
the center with the source protein. Epitopes that have cross-reactive partners are fairly dispersed – each is relatively 
unique, with few shared ninemers in the human genome. The lower-risk protein (metalloproteinase inhibitor 2) clearly 
has a big group of epitopes with cross-reactive partners, though each has only one or two matches in the human 
genome. 
Genomic-scale analysis 
We used CHOPPI’s genome filter to identify CHOPs that are likely to be expressed, secreted, or both. To predict 
expression and secretion, by homology matching the CHO genome against the CHO transcriptome, CHO proteome, 
and mouse secretome, it is necessary to establish required levels of sequence identity and coverage. We considered 
three different alternatives: 50% identity covering at least 50% of the sequence (relatively loose matches), to 70% 
identity at 70% coverage (moderate), and 90% identity at 90% coverage (tight). We also employed the SignalP-
based secretion filter. Table 1 summarizes the number of proteins from the 24,238 in the CHOPPI-processed CHO 
genome, meeting different transcription and secretion criteria. It shows that the different criteria produce different sets 
of proteins, making trade-offs between possible false positives (including CHOPs that will not actually be present in 
recombinant therapeutic preparations) and false negatives (excluding CHOPs actually present). We note that at 
higher identity and coverage cutoffs, a number of secreted proteins from mouse did not have homologs in CHO.  
For the remaining results, we adopted the moderate criteria of 70% identity at 70% coverage as a reasonable 
balance. Figure 3(b,d,f) illustrates these immunogenicity score distributions with estimated density plots (essentially 
smoothed histograms as described in the Methods section “Data analysis and visualization”). The supplementary 
material includes corresponding cumulative distributions from which one can infer what fraction of each dataset falls 
above or below various thresholds. We now discuss the overall characteristics of the plots; the following subsection 
details some of the interesting risky CHOPs highlighted on the plots. 
Whole-protein immunogenicity score. To assess the overall predicted immunogenicity of the filtered proteins, we 
first evaluated each CHO protein on the EpiMatrix whole-protein immunogenicity scale, which is calibrated such that 
a score above 20 indicates a relatively high-risk protein and a score below −20 indicates a protein that is predicted to 
be non-immunogenic. Figure 3(b) shows the distribution of EpiMatrix immunogenicity scores over the different protein 
sets. Most of the proteins in each subset have medium or low epitope density and thus do not pose a clear 
immunogenicity risk. But clearly, each subset includes some proteins with a high risk of immunogenicity (EpiMatrix 
immunogenicity score above 20); this is further illustrated by the cumulative distribution (see supplementary 
material). The tails of the distributions are fairly long (even including secondary peaks in the secreted proteins), 
yielding sizable numbers of proteins with high overall EpiMatrix immunogenicity scores.  
Epitope content. Focusing on the epitope content of individual proteins, Figure 3(d) shows that in each set, proteins 
tend to have 20-40 epitopes (i.e., ninemers predicted to bind at least one MHC allele). Clearly, this depends on 
protein length; for example, for abnormal spindle-like microcephaly-associated protein, 587 epitopes are predicted for 
this 1831 amino acid protein (not shown). As with the overall protein immunogenicity score, the genomic-scale 
analysis by CHOPPI enables the user to see that each set of proteins includes some with substantial numbers of 
epitopes. 
CHO-unique epitope content. While the overall EpiMatrix immunogenicity score and individual epitope count are 
indicative of the potential for immunogenicity, these scores do not incorporate any adjustment for conservation with 
autologous (human) proteins and thus may overestimate immunogenic risk. Figure 3(f) complements these 
assessments by illustrating the numbers of CHO-unique epitopes, i.e., those that lack cross-reactivity with autologous 
proteins and thus are most likely to induce a detrimental immune response. Due to the overall homology between 
CHOPs and their human protein counterparts, many of the CHO epitopes do indeed have homologous partners and 
can be predicted to have low immunogenicity and unlikely to break peripheral tolerance. However, we still see a 
number of proteins in any genomic subset with a substantial number of unique epitopes (even by the relaxed 
JanusMatrix evaluation that allows variation in the MHC-facing residues). The potential for these slightly dissimilar 
proteins to cross-react and induce immune responses under the right inflammatory circumstances can be predicted 
from published experience e.g., with autoimmune disease models in which the immunogen is often the human 
version of the murine autoimmune disease target such as in the use of human thyroid stimulating hormone receptor 
in the induction of a murine Graves’ disease model. More specifically, it is well known that a single epitope difference 
can trigger an immune response against a self protein that then spreads to other epitopes (You and Chatenoud, 
2006; McLachlan et al., 2012; Inaba et al., 2013).  
Overall human homology. To further evaluate the effects of homology, we identified those proteins from the 
transcriptome set that also have global sequence-level (not necessarily epitope-level) homology to a human protein. 
Such proteins thus are likely to be expressed and are overall quite similar to human proteins, but they may still have 
segments that are immunologically risky. Figure 5 illustrates the distributions of the percent of epitopes that are CHO-
unique, over the proteins in a set with 70% identity to human at 70% coverage, as well as in a set with 90% identity at 
90% coverage. Strikingly, even though the overall human homology of these CHOPs is quite high, there are 
substantial numbers of epitopes in some proteins that do not appear in any human protein, even in a relaxed 
JanusMatrix cross-reactivity evaluation. In the 70% at 70% set, 298 proteins have at least 40% of their epitopes as 
unique to CHO, while even in the 90% at 90% set, 13 proteins have at least 40% CHO-unique epitopes. 
Example Risky CHOPs 
For further analysis (described below) we focused on the set of transcribed, secreted proteins as representatives of 
those likely to be found in CHO cultures. A detailed spreadsheet with the CHOPPI analysis of all 35 proteins is 
provided in the supplementary material and an interactive version is available on the CHOPPI site. Several 
examples, highlighted on the graphs in Figure 3(b,d,f), illustrate the immunogenicity risks posed by some of the 
proteins in the tails of the distributions. These risky proteins were not selected from the set above that was pre-
filtered to have high human homology, but we note that they do all have at least 60% identity with a human homolog 
and yet retain novel epitopes that pose an immunogenicity risk. 
High EpiMatrix immunogenicity scores and epitope content. Of the 35 proteins, eight were identified as having 
EpiMatrix whole-protein immunogenicity scores above 20 (Figure 3b), indicating a stronger immunogenicity risk. Of 
these, C-X-C motif chemokine 3 (CXCC3) has a score of 92, due to the presence of 22 epitopes (Figure 3d) within 
only 101 amino acids total length. However, only three of these epitopes are unique to CHO (Figure 3f) according to 
the JanusMatrix analysis, and thus we would expect that the chemokine might not be as immunogenic as indicated 
by the raw EpiMatrix immunogenicity score. There are similar stories for pigment epithelium-derived factor (score of 
62 with four CHO-unique epitopes among 14 epitopes in 58 amino acid residues) and leukemia inhibitory factor 
(score of 56 with five CHO-unique epitopes among 30 in 158 residues) (not shown). However, we see a slightly 
higher level of CHO-unique epitopes in gamma-glutamyl hydrolase (score of 41 with 25 unique epitopes among 58 in 
271 residues) and metalloproteinase inhibitor 1 (score of 40 with 16 unique epitopes among 40 in 203 residues) (not 
shown). 
High CHO-unique epitope content. Sorting the proteins by their numbers of CHO-unique epitopes leads to the 
observation that the heavy tail in this distribution (Figure 3f) is due to large proteins such as lysosomal alpha-
mannosidase (LAM; 68 CHO-unique epitopes of 192, within 1009 residues total), sialate O-acetylesterase (43 of 102 
in 550), and complement C1r-A subcomponent (34 of 102 in 705). The middle of the distribution has a number of 
cathepsins (cathepsin B with 27/52 unique, D with 21/76, and L1 with 18/52), along with a wide range of other 
proteins such as a macrophage colony-stimulating factor 1 (MCSF1), an extracellular matrix protein, and granulins. 
Sorting instead on the percentage of epitopes that are CHO-unique (not shown) reveals a few additional proteins with 
relatively high CHO-unique epitope density, including plasminogen activator inhibitor 1 (11% of epitopes are CHO-
unique), lactadherin (8.3%), and metalloproteinase inhibitor 1 (8.2%). The relatively high CHO-unique epitope content 
of metalloproteinase inhibitor 1 stands in contrast to that of its homolog metalloproteinase inhibitor 2 (38% sequence 
identity over a 167-residue aligned fragment), which as discussed above only has a single CHO-unique epitope. 
Epitope content is a function of the particular constituent peptides, and can thus be quite different even among 
overall similar proteins, highlighting the need for protein-specific analysis of immunogenicity risk along with 
expression/secretion risk. 
High CHO-unique epitope content, despite high overall human identity. Recall that the distribution of epitope 
conservation in CHO proteins with close human homologs (Figure 5) reveals a number of CHOPs with high relative 
CHO-unique epitope content. Even in the extremely homologous set of 90% identity at 90% coverage, we are able to 
identify some proteins with substantial potential for immunogenicity, by having a sizable CHO-unique percentage of 
epitopes within a high overall number of epitopes. For example, calreticulin has a 94% identical human homolog, yet 
the CHO version has five CHO-unique epitopes among the 43 that are identified in this protein, over its 417 residues. 
Reticulocalbin-2 has nine CHO-unique epitopes out of a total of 39 despite having a 92% identical homolog in the 
human genome. And connective tissue growth factor has a 91% identical homolog, still leaving seven of 31 unique 
epitopes in only 348 amino acids. These proteins thus have the potential for driving a detrimental immune response 
with their “foreign” epitopes, potentially even spreading to the remaining more “human” epitopes once the attention of 
the immune system is raised. 
Epitope-level analysis of one protein from each of these categories was conducted: CXCC3 representing the high 
whole-protein immunogenicity group, LAM the high CHO-unique group, and reticulocalbin-2 the high-unique though 
high-human identity group. Figure 4 (right) presents visualizations of the networks of cross-reactive epitopes. 
Differences between protein CXCC3 and LAM are noticeable. The network for CXCC3 shows high conservation with 
human proteins, and there are few CHO-unique epitopes near the CXCC3 node. In contrast, the LAM epitope 
network shows several such epitopes, which are concentrated around LAM. We also note that CXCC3 has fewer 
predicted epitopes in general than LAM, but because CXCC3 has more cross-reactive epitopes with human proteins, 
its branches are more populated. Moreover, the CXCC3 network has more connections due to the presence of cross-
reactive epitopes in multiple human proteins. In addition, one epitope from CXCC3 is cross-reactive with numerous 
(637) human epitopes, further populating the network. Analogous high cross-reactivity with the human genome was 
observed in Tregitopes and an HCV regulatory epitope (Moise et al., 2013). Thus, CXCC3 might induce a regulatory 
immune response in humans. Finally, reticulocalbin-2 looks much like the riskier validated proteins annexin A1 and 
lysosomal protective protein, with a cluster of CHO-unique epitopes near the protein and the cross-reactive epitopes 
dispersed away from it. 
Conclusion 
CHOPPI provides a powerful new resource for computationally predicting the immunogenicity risk of CHO proteins, 
whether previously identified by experimental techniques or selected from a genomic analysis according to factors 
affecting whether the CHOP would be hitchhiking along during the purification process of a therapeutic product. We 
show by examination of validated CHOPs, as well as by discovery of new potentially risky CHOPs, that CHOPPI 
reveals important aspects of CHOP risk, including the potential to be present in cell culture medium, and whether the 
protein contains many unique CHO epitopes, which could contribute to the stimulation of a detrimental immune 
response. CHOPPI enhances currently available experimental methods by summarizing and detailing the 
contributions of individual T cell epitopes to immunogenic risk, and accounts for both epitope density and similarity to 
autologous proteins. An important take-away message is that the CHO genome contains many proteins that are 
substantially dissimilar to the human genome from the T cell epitope standpoint, and thus inherently do pose some 
risk of triggering anti-self immune responses. This finding supports the current FDA and EMA perspectives on CHOP; 
that lower levels of CHOPs are important for drug safety (FDA, 2012; EMA, 2012). 
We intend to continue expansion and generalization of CHOPPI’s capabilities. We will incorporate additional 
genomic, transcriptomic, proteomic, and secretomic information as these databases continue to be generated. We 
will also continually expand the set of validated CHOPs identified within CHOPPI. CHOPPI provides a general-
purpose architecture for HCP analysis, and we may apply it to other cell lines that are commonly used to produce 
protein therapeutics.  
CHOPPI’s results are all predictive in nature, based on computational analyses. A key next step is the experimental 
validation of CHOPPI predictions. We intend ourselves to experimentally test immunogenicity of internally identified 
CHOPs as well as support others in doing so by making this resource available (http://www.immunome.org/CHOPPI). 
In general, CHOPPI provides a valuable resource for focusing follow-up experimental characterization and 
immunogenicity studies on the possible impurities of greatest predicted importance and relevance. 
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Table 
Table 1. Subsets of CHO-K1 genes (24,238 processed in CHOPPI) that are predicted to be transcribed and/or 
secreted. 
Subset 50% id 
@ 50% cov 
70% 
@ 70% 
90% 
@ 90% 
Transcriptome 10,157 (41.91% a) 7,114 (29.35%) 4,536 (18.71%) 
Proteome 8,626 (35.59%) 6,526 (26.92%) 5,018 (20.70%) 
Mouse secretome 288 (1.19%) 165 (0.68%) 46 (0.19%)  
Transcriptome 
     & mouse secretome 
76 (0.31%) 35 (0.14%) 5 (0.02%) 
Transcriptome 
     & SignalP 
571 (2.36%) 367 (1.51%) 251 (1.04%) 
Transcriptome 
     & mouse secretome 
     & SignalP 
36 (0.15%) 23 (0.09%) 2 (0.01%) 
aPercentage of the CHO-K1 genes processed in CHOPPI represented in the subset. 
Summary of the number of proteins from the CHO genome that are predicted to be transcribed and/or secreted. 
Different identity (id) and coverage (cov) percentages produced different sets of proteins. 70% identity at 70% 
coverage was used for subsequent results. 
 
Figures 
Figure 1. The CHOPPI web tool. CHOPPI allows two types of searches, “CHOP query” and “genome filter”, along 
with the ability to browse a set of validated CHOPs. These all lead into individual protein reports. (a!b) CHOP 
query. In this example, a fragment of an amino acid sequence is used as a query and CHO homologs to the query 
protein are identified. (a!c) Genome filter. In this example, the CHO genome is filtered for proteins with homology 
matches to both a CHO transcriptome and a CHO proteome, along with presence of a predicted signal peptide. The 
analysis of the filtered proteins is presented in a table. As with the CHOP query, an individual protein can then be 
examined. (a!d) The dataset of experimentally identified CHOPs. (one of {b, c, or d} !e) Individual protein report 
linked from the previous panel (boxed in each). The page summarizes both predicted epitope content (EpiMatrix 
whole-protein immunogenicity score, along with number and density of epitopes and CHO-unique epitopes), and 
predicted presence in protein production (homology matches against a CHO transcriptome, a CHO proteome, a 
mouse secretome, a set of validated CHOPs, and/or appearance of a predicted signal peptide). Immunogenicity 
evaluations are plotted relative to distributions over the whole genome. 
 
Figure 2. Filtering the CHO genome. CHOPPI enables selection of CHO protein subsets by homology matching 
with a CHO transcriptome, a human proteome, a mouse secretome, and the human genome, along with testing for 
the presence of a predicted signal peptide. 
 
Figure 3. Immunogenicity evaluations over different sets of CHOPs. The left panels (a,c,e) characterize the 
validated CHOPs with histograms. Examples of validated CHOPs and their scores are shown: collagen (COLL), 
lysosomal protective protein (LPP), annexin A1 (A1), and metalloproteinase inhibitor 2 (MPI2). The right panels (b,d,f) 
characterize various genome-filtered subsets with density estimates (smoothed histograms). Note that the y-axes of 
the density plots are differently scaled. Subsets: CHO genome, CHO transcriptome (transcr), CHO proteome, mouse 
secretome (secr), intersection of transcr with secr, intersection with predicted CHOPs containing predicted signal 
peptides (SignalP), intersection with secr and SignalP, and validated CHOPs (repeated from the left panels). 
Examples of potential immunogenic proteins and their scores (in parenthesis) are shown: C-X-C motif chemokine 3 
(CXCC3), macrophage colony-stimulating factor 1 (MCSF1), and lysosomal alpha-mannosidase (LAM). (a,b) Overall 
protein immunogenicity, truncated to show proteins scoring between -100 to 100 on the EpiMatrix immunogenicity 
scale. A red line indicates the level at which a protein is considered to be higher risk (EpiMatrix score of 20). (c,d) 
Number of epitopes within a protein, truncated to 100. (e,f) Number of epitopes within a protein that are not human-
like, according to cross-reactivity analysis using JanusMatrix, truncated to 100.  
 
Figure 4. Cross-reactivity analysis of example CHOPs. (left) Validated CHOPs and (right) CHOPPI-identified 
immunologically risky CHOPs. In the epitope network visualizations, CHOPs are shown as green diamonds (one per 
network), their epitopes as either red squares (no cross-reactive epitopes) or gray squares (one or more), their cross-
reactive partners in the human genome as blue triangles, and the source human proteins as light purple circles. 
 
Figure 5. CHOP cross-reactivity with human. CHO-unique epitope content within CHOPs that have matches in 
both the CHO transcriptome (70% identity at 70% coverage) and the human genome (either with 70% identity at 70% 
coverage or with 90% at 90%). CHOPs that are more cross-reactive with human proteins at the protein and epitope 
level are less likely to induce a T effector response. Conversely, even those CHOPs that are highly conserved may 
have one or more CHO-unique epitopes that could contribute to anti-CHOP immune response (with potential for 
spreading to the more conserved epitopes).  
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